Cell and Gene Therapy Today—April 30, 2026

This week’s Gene and Cell Therapy update highlights regulatory milestones, clinical progress, delivery advances, regional launches, and manufacturing partnerships.

In Today’s Newsletter

Dive deeper

🧬 Intellia starts rolling FDA BLA for lonvo-z in HAE [1] [US • 27 Apr 2026]

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-initiates-rolling-submission-biologics
Context: Lonvoguran ziclumeran (Intellia; lonvo-z, formerly NTLA-2002) is an in vivo CRISPR candidate targeting KLKB1 for hereditary angioedema.
Key point: Intellia initiated a rolling FDA BLA and expects to complete submission in H2 2026, with potential launch in H1 2027 if approved.
Implication: May influence prescriber choice and payer reviews pending full data.

👂 Regeneron’s Otarmeni wins FDA approval for genetic hearing loss [2] [US • 23 Apr 2026]

https://www.fiercepharma.com/pharma/regeneron-ushers-new-genetic-medicine-era-groundbreaking-gene-therapy-approval
Context: Otarmeni (Regeneron; DB-OTO) delivers a functional otoferlin gene for a rare inherited form of hearing loss.
Key point: FDA approved Otarmeni, according to Fierce, making it Regeneron’s first approved gene therapy.
Implication: Introduces a new genetic medicine option for a narrow pediatric hearing-loss population.

🧠 Apertura and Broad to present TfR1 CapX CNS delivery data at ASGCT [3] [US • 27 Apr 2026]

https://www.prnewswire.com/news-releases/apertura-gene-therapy-and-scientists-from-the-broad-institute-to-share-data-on-tfr1-capx-a-novel-capsid-targeting-the-central-nervous-system-cns-at-the-american-society-of-gene-and-cell-therapy-asgct-annual-meeting-302754667.html
Context: TfR1 CapX (Apertura; AAV capsid) uses human transferrin receptor 1 to support intravenous CNS delivery.
Key point: Apertura and Broad scientists will present ASGCT 2026 updates on clinical-scale manufacturing, preclinical models, Open Aperture, and CNS payload applications.
Implication: Signals pipeline investment and modality expansion.

🩸 Orca Bio gains RMAT designation for Orca-Q [4] [US • 28 Apr 2026]

https://www.biospace.com/press-releases/orca-bio-announces-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-orca-q-for-the-treatment-of-high-risk-hematologic-malignancies
Context: Orca-Q (Orca Bio) is an investigational allogeneic T-cell immunotherapy in Phase 1 for high-risk hematologic malignancies.
Key point: FDA granted RMAT designation based on preliminary Phase 1 data across survival, GVHD, and non-relapse mortality measures.
Implication: May support faster FDA interaction and potential expedited review pathways.

🔗 InVita and Gulf Coast Blood add CGT donor workflows to HemaConnect [5] [US • 23 Apr 2026]

https://www.prnewswire.com/news-releases/invita-healthcare-technologies-and-gulf-coast-blood-advance-cell-and-gene-therapy-donor-recruitment-through-hemaconnect-2-5–302750906.html
Context: HemaConnect 2.5 (InVita Healthcare Technologies) adds donor recruitment, scheduling, and tracking workflows for cell and gene therapy.
Key point: InVita and Gulf Coast Blood expanded the platform to support advanced therapy donor operations alongside traditional blood-center collections.
Implication: May expand screening, initiation, and follow-up at scale.

🦴 Biosolution’s CartiLife enters China knee osteoarthritis market [6] [China • 28 Apr 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31465
Context: CartiLife (Biosolution) is an autologous costal chondrocyte-derived cell therapy for knee cartilage defects.
Key point: Biosolution said CartiLife received final sales approval in Hainan and will enter China through the medical tourism pilot zone.
Implication: Introduces competition that may affect pricing and formulary access.

🧫 South Korea clears VT-EBV-N regenerative therapy plan [7] [South Korea • 24 Apr 2026]

https://biz.chosun.com/en/en-science/2026/04/24/LAIVT3NGVJGCLB2QS2TPUFXFCQ/
Context: VT-EBV-N (ViGenCell) is an autologous EBV-specific immune cell therapy for EBV-positive NK/T-cell lymphoma after complete remission.
Key point: South Korea approved a treatment plan at The Catholic University of Korea Yeouido St. Mary’s Hospital for 15 participants at high relapse risk.
Implication: May expand screening, initiation, and follow-up at scale.

🛠️ CHA Biotech and Miltenyi Biotec collaborate on CAR-NK manufacturing [8] [South Korea • 28 Apr 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31460
Context: CHACAR-NK-201 (CHA Biotech) is an allogeneic CAR-NK anticancer cell therapy candidate.
Key point: Miltenyi Biotec will produce and supply lentiviral vectors, including BaEV platform capabilities, to support CHA Biotech’s CAR-NK development.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

FDA pathways remain central, with Intellia’s rolling BLA and Orca Bio’s RMAT designation pointing to accelerated regulatory engagement. [1][4]
Genetic medicines are moving into specialized non-oncology settings, including HAE and rare inherited hearing loss. [1][2]
CNS delivery remains a core bottleneck, with Apertura and Broad highlighting capsid engineering, model selection, and manufacturing scale. [3]
Korea-linked cell therapy programs are gaining regional traction through China’s Hainan pathway and South Korea’s regenerative medicine framework. [6][7]
Manufacturing and donor infrastructure are becoming competitive differentiators for CGT scale-up. [5][8]

🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

📚 See the full Cell and Gene Therapy archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

FAQ

What is lonvo-z from Intellia Therapeutics?

Lonvo-z is an in vivo CRISPR gene-editing candidate intended as a one-time treatment for hereditary angioedema by targeting KLKB1. Intellia has started a rolling FDA BLA. [1]

What did FDA approve for Regeneron?

FDA approved DB-OTO as Otarmeni for otoferlin-related hearing loss, according to Fierce. The therapy delivers a functional otoferlin gene into the ear. [2]

What is TfR1 CapX from Apertura Gene Therapy?

TfR1 CapX is an AAV capsid designed to use human transferrin receptor 1 for intravenous delivery to the brain and spinal cord. Apertura and Broad will present related ASGCT data. [3]

Why is Orca-Q’s RMAT designation relevant?

RMAT designation may provide more FDA interaction and eligibility for expedited pathways. Orca-Q is being studied in high-risk hematologic malignancies. [4]

What is CartiLife’s China pathway?

Biosolution said CartiLife received final sales approval in Hainan through the medical tourism pilot zone, not the conventional NMPA pathway. [6]

What are CHA Biotech and Miltenyi Biotec building together?

They are collaborating on lentiviral vector supply and scalable manufacturing support for allogeneic CAR-NK therapies, including CHA Biotech’s CHACAR-NK-201. [8]

Entities / Keywords

Intellia Therapeutics, lonvoguran ziclumeran, lonvo-z, NTLA-2002, hereditary angioedema, HAE, KLKB1, CRISPR, rolling BLA, RMAT
Regeneron Pharmaceuticals, DB-OTO, Otarmeni, otoferlin, genetic hearing loss, gene therapy, Decibel Therapeutics
Apertura Gene Therapy, Broad Institute, TfR1 CapX, AAV capsid, hTfR1, CNS delivery, ASGCT 2026, Open Aperture
Orca Bio, Orca-Q, allogeneic T-cell immunotherapy, high-risk hematologic malignancies, GVHD, RMAT
InVita Healthcare Technologies, Gulf Coast Blood, HemaConnect 2.5, CGT donor recruitment, donor scheduling
Biosolution, CartiLife, autologous costal chondrocyte-derived cell therapy, knee osteoarthritis, Hainan Medical Tourism Pilot Zone
ViGenCell, VT-EBV-N, EBV-positive NK/T-cell lymphoma, Yeouido St. Mary’s Hospital, advanced regenerative medicine
CHA Biotech, Miltenyi Biotec, CHACAR-NK-201, CAR-NK, allogeneic NK cells, lentiviral vectors, BaEV platform